Mirum Pharmaceuticals Inc

Latest Results (11.10.2025):

Mirum Pharmaceuticals Inc. reported strong financial results for the second quarter of 2025, achieving total revenues of $128 million. The company has raised its 2025 revenue guidance to a range of $490 to $510 million, reflecting robust growth in both its international business and U.S. PFIC launch. Mirum remains optimistic about its pipeline, anticipating significant clinical milestones in 2026.

Increased Revenue Guidance

Mirum Pharmaceuticals Inc. has raised its full-year 2025 revenue guidance to between $490 and $510 million, up from previous estimates. This adjustment highlights the company's confidence in its commercial strategies and market performance.

Strong Product Sales

For the second quarter of 2025, Mirum reported global net product sales of $127.8 million. LIVMARLI® achieved net sales of $88.2 million, marking an 87% increase compared to the same quarter in 2024. Additionally, Bile Acid Medicines saw net sales of $39.6 million, reflecting a 30% growth year-over-year.

Advancements in Pipeline

The company is progressing toward multiple key milestones in 2026, including the completion of enrollment for the VISTAS study of volixibat in PSC and the reporting of topline data in the second quarter of next year. Mirum is also preparing to initiate a Phase 2 study for MRM-3379 in Fragile X Syndrome in the fourth quarter of 2025.

Robust Financial Position

As of June 30, 2025, Mirum maintains a strong balance sheet with $321.7 million in unrestricted cash, cash equivalents, and investments. Operating expenses for the quarter were $132.8 million, which includes $24.5 million in non-cash expenses, up from $102.1 million in the same period last year.